Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients

HIV Clinical Trials

Volumn 14, Issue 5, 2013, Pages 183-191

  Wood, Robin ^a   Gathe, Joseph ^b   Givens, Naomi ^c   Sedani, Sangeeta ^c   Cheng, Katharine ^c   Sievers, Jörg ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Therapeutic Concepts   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

fosamprenavir; long term safety; protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; FOSAMPRENAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRIGLYCERIDEMIA; HYPOXEMIA; INFECTION; INFESTATION; LEUKOPENIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OPEN STUDY; PANCREATITIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEPTICEMIA; SIDE EFFECT; SUDDEN DEATH; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD;

FOSAMPRENAVIR; LONG-TERM SAFETY; PROTEASE INHIBITORS;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CARBAMATES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHATES; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD; YOUNG ADULT;

EID: 84886545983     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1405-183     Document Type: Article

References (27)

1. Mocroff A, Ledergerber B, Katlama C, et al; for the Euro-SIDA Study Group. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003;362:22-29. (Pubitemid 36835816)
2. Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS. 2005;19:2009-2018. (Pubitemid 41669026)
3. Gandhi T, Wei W, Amin K, Kazanjian P. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late stage HIV infection and inadequate response to therapy. Clin Infect Dis. 2006;42:878-884. (Pubitemid 43363948)
4. Gandhi T, Nagappan V, Cinti S, et al. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen. Clin Infect Dis. 2007;45:1085-1092. (Pubitemid 47591520)
5. Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defi ning events in patients with uncontrolled viral replication and profound immunodefi ciency. Clin Infect Dis. 2008;46:296-304. (Pubitemid 351269173)
6. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Offi ce of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. February 12, 2013. http://aidsinfo.nih. gov/contentfi les/lvguidelines/adultandadolescentgl. pdf. Accessed March 14, 2013.
7. European AIDS Clinical Society (EACS) guidelines for treatment of HIV-infected adults in Europe. November 2012. http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6. 1-2edition.pdf. Accessed March 14, 2013.
8. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: A 48-week open-label study to compare the antiviral effi cacy and safety of GW433908 versus nelfi navir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defi c Syndr. 2004;35:22-32. (Pubitemid 38044778)
9. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week effi cacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfi navir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537. (Pubitemid 39037477)
10. DeJesus E, Lamarca A, Sension M, et al. The Context Study: Effi cacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Presented at: 10th Conference of Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, MA, USA. Abstract 178.
11. Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of FPV and amprenavir in human immunodefi ciency virus type 1-infected patients. Antimicrob Agents Chemother. 2004;48:116-123. (Pubitemid 38040186)
12. GSK Clinical Study Register. AZL30006: A phase IIIb/IV, randomized, open label, multicenter, pilot trial to explore the safety and tolerability of GW433908 +/-ritonavir (1400 mg twice daily or 700 mg/100 mg twice daily) when used in combination with a zidovudine-containing regimen (Trizivir or Combivir twice daily) over a 24 week period in antiretroviral therapy naive HIV-1 infected subjects. www.gsk-clinicalstudyregister.com. Accessed August 7, 2013.
13. Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defi c Syndr. 2005;40:422-427. (Pubitemid 41669175)
14. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defi c Syndr. 2006;43:284-292. (Pubitemid 44674008)
15. Pulido F, Katlama C, Marquez M, et al. A randomized study investigating the effi cacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults. HIV Med. 2004;5:296-302. (Pubitemid 39077123)
16. GSK Clinical Study Register. PROAB3007: An open-label phase III study to assess the long term safety profi le of amprenavir (141W94) containing regimens in HIV infected subjects. www.gsk-clinicalstudyregister.com. Accessed August 7, 2013.
17. Eron JJ Jr, Park JG, Haubrich R, et al; ACTG5126 Study Team. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009;53:2335-2341.
18. Centers for Disease Control and Prevention. 1993 Revised classifi cation system for HIV infection and expanded surveillance case defi nition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
19. Division of AIDS, National Institute of Allergy and Infectious Diseases. Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: NIAID; 1992.
20. Division of AIDS, National Institute of Allergy and Infectious Diseases. Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: NIAID; 2004.
21. Gathe JC Jr, Wood R, Sanne I, et al. Long-term (120-week) antiviral effi cacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naïve patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006;28:745-754. (Pubitemid 44173054)
22. Bellos N, Clumeck N, Bleiber G, et al. Sustained virologic and immunologic response over 180 weeks in antiretroviral therapy (ART)-naïve subjects receiving fosamprenavir/ritonavir (FPV/RTV) QD. Presented at: 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK. Abstract P13.
23. Friis-Møller N, Reiss P, Sabin CA, et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735. (Pubitemid 46658704)
24. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-1238.
25. Murphy RL, da Silva B, Hicks CB, et al. Seven-year effi-cacy of a lopinavir/ritonavir-based regimen in antiretroviralnaïve HIV-1-infected patients. HIV Clin Trials. 2008;9:1-10. (Pubitemid 351214236)
26. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482. (Pubitemid 44160731)
27. Pulido F, Estrada V, Baril JG, et al. Long-term effi cacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials. 2009;10:76-87.